Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation
PERTH, Australia, Jan. 23, 2018 /CNW/ -- Zelda Therapeutics (ASX: ZLD), based in Australia, focused on medical cannabis therapies, today announced that the January 18 presentation from Dr. Stewart Washer, Executive Director, is now available for on-demand viewing at VirtualInvestorConferences.com.
Zelda Therapeutics' presentation will be available 24/7 for 90 days. Investors and advisors may download shareholder materials from the "virtual trade booth" for the next three weeks.
Recent Company Highlights
- In December 2017 Zelda Therapeutics announced its collaboration with the Children's Hospital of Philadelphia for an observational study of cannabinoids on autism.
- Recently received Australia's first regulatory approval to conduct a medicinal cannabis trial to treat chronic insomnia.
- Zelda has shown a positive effect with their cannabis extracts on human breast cancer cell lines
- Zelda is now studying cannabis extracts on pancreatic and brain cancer cell lines
About Zelda Therapeutics
Zelda Therapeutics Limited ("Zelda") is an Australian biotechnology company which listed on the Australian Stock Exchange (ASX) in 2016, trading under the ASX code "ZLD". The company is developing medicinal cannabis therapies in collaboration with a number of key international leaders and research organisations. Zelda has exclusive access to comprehensive patient data that has demonstrated therapeutic success using cannabinoid-based treatments and has leveraged this to commence pre-clinical research in breast, brain and pancreatic cancer and will commence human clinical trials in 2018 on a number of other disorders including insomnia and autism.
Since 2010, VirtualInvestorConferences.com, created by BetterInvesting (NAIC) and PRNewswire, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with investors using a graphically-enhanced online platform.
Designed to replicate the look and feel of location-based investor conferences, Virtual Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.
SOURCE Zelda Therapeutics
For further information: Zelda Therapeutics: Stewart Washer, Executive Director, +61 418 288 212, email@example.com; VirtualInvestorConferences.com: John Viglotti, VP, Investor Relations Products and Services, Cision / PR Newswire / MultiVu, +1.201.360.6767, firstname.lastname@example.org